{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 2134"}, "official-title": {"#tail": "\n\t", "#text": "To withdraw approval for the drug Zohydro ER and prohibit the Food and Drug Administration from\n\t\t\t approving such drug unless it is reformulated to prevent abuse. "}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140313", "#text": "March 13, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "sponsor": {"#tail": " introduced the following bill; which was read twice and referred to the ", "#text": "Mr. Manchin", "@name-id": "S338"}, "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor, and Pensions"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Act to Ban Zohydro", "@value": "Act to Ban Zohydro", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n\t\t\t", "#text": "1."}, "header": {"#tail": "\n\t\t\t", "#text": "Short title"}, "#text": "\n\t\t\t", "@id": "H1BC2D7D3AC3347729406876EF745ACED"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " finds as follows:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n\t\t\t", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The drug Zohydro ER is a high-dose hydrocone-only opioid narcotic painkiller listed in schedule II\n\t\t\t of ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 202(c) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:202/ss:c"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 812(c)", "@value": "usc/21/812/c"}, "@parsable-cite": "usc/21/812", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(1)"}, "@id": "H57D0A956B2E849C39749AF36763CCB5A", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " Anesthetic and Analgesic Drug Products Advisory Committee report\n\t\t\t cited available\n\t\t\t dosages of Zohydro ER that, according to health care and substance abuse\n\t\t\t professionals, have up to 10 times more hydrocodone than any hydrocodone\n\t\t\t painkiller currently on the market.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(2)"}, "@id": "H84333C24DE35461896F9C12C9B0B5574", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Zohydro ER is manufactured without an abuse deterrent formulation."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(3)"}, "@id": "HBC139636E194437B9FFED7A18DFD0C1F", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Zohydro\u2019s time-released effect, an important element of its pharmaceutical use, is easily negated\n\t\t\t by abusers to achieve a heroin-like effect."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(4)"}, "@id": "HB4685675C919466BB22361BFB025A72D", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The Anesthetic and Analgesic Drug Products Advisory Committee concluded that, if approved and\n\t\t\t marketed, Zohydro ER\n\t\t\t will be abused, possibly at a rate greater than that of currently\n\t\t\t available hydrocodone combination products."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(5)"}, "@id": "HAB8D235ED267480AA34C8495A20C6051", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The Anesthetic and Analgesic Drug Products Advisory Committee voted 11 to 2 against approval of\n\t\t\t Zohydro ER, citing the high possibility for addiction."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(6)"}, "@id": "H6A6E97092E834960B2A3FCB6C6DB6A84", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " approved Zohydro ER without an abuse deterrent formulation despite\n\t\t\t the fact that the Anesthetic and Analgesic Drug Products Advisory\n\t\t\t Committee voted 11 to 2 against doing so.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(7)"}, "@id": "H84B73D50F81147DA90F5061E04388557", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " has acknowledged that the widespread abuse of opioid drugs across\n\t\t\t the country has reached epidemic proportions in some parts of the country.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(8)"}, "@id": "H363E0F61678545FAB0CE7ADE17EF478F", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", deaths connected to prescription\n\t\t\t opioids have more than quadrupled in the United States, from 4,030 deaths\n\t\t\t involving the painkillers in 1999 to 16,651 deaths in 2010.", "@entity-type": "federal-body", "#text": "Centers for Disease Control and Prevention", "@entity-id": "7523"}, "#text": "According to the "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(9)"}, "@id": "H58537A878CB1419F9E8F26293BFD8BFC", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " has identified reducing deaths attributable to\n\t\t\t prescription painkiller abuse and overdose as a top health priority for\n\t\t\t 2014.", "@entity-type": "federal-body", "#text": "Centers for Disease Control and Prevention", "@entity-id": "7523"}, "#text": "The "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(10)"}, "@id": "H135BA662294C4B1DAE8D3BA978CB6D58", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to reconsider its\n\t\t\t approval of Zohydro ER.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "Attorneys General from 28 States have asked the "}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(11)"}, "@id": "H59B228C40A3E407A80BC558D28B7B32B", "#text": "\n\t\t\t\t"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Health care professionals, addiction treatment providers, and community-based drug and alcohol\n\t\t\t prevention programs are groups opposed to the approval of Zohydro ER."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(12)"}, "@id": "HD94CB7D988EC4D7E865A1F5B4049B896", "#text": "\n\t\t\t\t"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The burdens of Zohydro ER to the public health outweigh its potential therapeutic benefits. Given\n\t\t\t that alternative pain medicines and methods are widely available, approval\n\t\t\t of Zohydro ER should be withdrawn until such time that there is available\n\t\t\t a Food and Drug Administration-approved abuse deterrent formulation."}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(13)"}, "@id": "HBEA3EF1E1CA5415598386CC23DDB4DBF", "#text": "\n\t\t\t\t"}], "#text": "\n\t\t\t", "@id": "H4B74B8AFBAB4407786E3B7E135CDB43C"}, {"#tail": "\n  ", "enum": {"#tail": "\n\t\t\t", "#text": "3."}, "header": {"#tail": "\n\t\t\t", "#text": "Withdrawal of approval of drug Zohydro ER"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Effective beginning on the day that is 45 days after the date of enactment of this Act, approval of\n\t\t\t the application with respect to pure hydrocodone bitartrate\n\t\t\t extended-release capsules (marketed as the drug Zohydro ER) under ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " is\n\t\t\t deemed to have been withdrawn under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section\n\t\t\t 505(c) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(c)", "@value": "usc/21/355/c"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 505(e) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:e"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C.\n\t\t\t 355(e)", "@value": "usc/21/355/e"}], "@entity-type": "law-citation", "#text": "\n            "}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Withdrawal of approval"}, "#text": "\n\t\t\t\t", "@id": "H98693F7455CD4FA29C87C4004C7D741C"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not approve any application under ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " for pure hydrocodone\n\t\t\t bitartrate extended-release capsules unless such drug is formulated to\n\t\t\t prevent abuse.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n\t\t\t\t", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "No approval of any formulation that is not abuse deterrent"}, "#text": "\n\t\t\t\t", "@id": "H4467A50BAFF34BD68D93A27F0FAAD478"}], "#text": "\n\t\t\t", "@id": "H39CB88465A744934B069C267CF69E860"}], "#text": "\n\t\t", "@id": "H1068DE95BDA94E6BAA52DA67D3E31761"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-03-13"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S2134 IS: Act to Ban Zohydro"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}